<DOC>
	<DOCNO>NCT01802853</DOCNO>
	<brief_summary>This open-label , randomize , 2-way crossover study ass absolute bioavailability pharmacokinetics RO6811135 healthy male volunteer . Subjects randomize one sequence AB BA receive single dos subcutaneous ( A ) intravenous ( B ) RO6811135 , washout period least 7 day dose .</brief_summary>
	<brief_title>A Bioavailability Pharmacokinetic Study Subcutaneous Intravenous RO6811135 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Male healthy volunteer , 1845 year age inclusive Healthy determine screen assessment Body mass index ( BMI ) 1830 kg/m2 Any clinically relevant history presence respiratory , renal , hepatic , gastrointestinal , hematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological connective tissue disease diseases History anaphylaxis severe systemic hypersensitivity allergic reaction Any history alcohol and/or drug abuse addiction past 5 year Smoking 5 cigarette day equivalent amount tobacco Any clinically relevant abnormal test result prior first dose Positive hepatitis B , hepatitis C HIV infection Participation investigational drug device study within 3 month prior Day 1 Period 1</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>